Radar · Traditional Pharmaceuticals in India
Best Traditional Pharmaceuticals Companies in India
The 1152 best Traditional Pharmaceuticals companies in India in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Mankind Pharma.
By Riya SenguptaFinancials
1152companies tracked
$3.4Bdisclosed funding
1unicorns
85have raised
India's Traditional Pharmaceuticals sector earns its scale the old-fashioned way: revenue. Our directory tracks 1,152 companies in India, ranked by disclosed equity funding and recent funding momentum, and the financials behind that list are staggering. Combined revenue across 1,135 filers hits $53.4B, with a median company pulling $3M at 8% annual growth. That's not hype, that's filed numbers.
The outsized earners make the median look almost quaint. Sun Pharmaceutical Industries booked $6.1B in revenue, growing 8% YoY, and netted $1.3B, which is 12,624 times the sector's median net income. Dr. Reddy's Laboratories added $3.8B at a sharper 17% clip. Aurobindo Pharma and Sun Pharma Distributors round out the top tier, each clearing $2B. So when you ask where serious capital is moving, the answer is here. Themes like generic drug approvals, prescription regulations and drug distribution are driving coverage, with investors like ChrysCapital and Baring Private Equity Partners backing the buildout. The one unicorn in the directory sits atop a funding stack of $3.4B total, and I'd expect that figure to climb as regulatory tailwinds keep compressing margins for smaller generics players while lifting the disciplined operators.
Sources & further reading
- India's CDMO market set to double by 2028 amid Asia's healthcare boom
- Pharma sector faces tariff threats amid rising US trade actions: Report
- India's pharma sector bullish on pushing up exports
FLIAR INTELLIGENCE · TRADITIONAL PHARMACEUTICALS × INDIA
Our analysis of 50 Traditional Pharmaceuticals companies
$3.2b in tracked funding; 51% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2016.
50companies analysed
51%cloud-native stacks
2016funding peak (by rounds)
1unicorns
1997median founding year
5Mcombined LinkedIn audience
78%of audience held by top 3
10companies hiring publicly (12 mo)
Ranked: Best Traditional Pharmaceuticals companies in India
| # | Company | Revenue | Disclosed funding | Last round | Revenue YoY | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Dr. Reddy's Laboratories Multinational pharmaceutical company that develops and manufactures innovative and medicines to improve… 83Moat top 12%Market top 18%Tech top 21%Product top 23% All 13 signals ▾Moattop 12% Markettop 18% Techtop 21% Producttop 23% Fin. healthtop 26% Patentstop 27% Innovationtop 33% Newstop 35% Talenttop 38% Fundingtop 44% Growthtop 46% Partnerstop 49% Globaltop 50% Moat: Top 1% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 6/10 Market: 21,757 employees (top 1% of Traditional Pharmaceuticals) · Revenue ~$4.0B rank vs industry peers · Fliar Intelligence Index 83/100 | $4.0B FY2025 | $4M | 15 mo ago | +17% | 21,757 21,757 → 32,580 (+50%) · sector median -6% | Erez Israeli CEO | 46 signals Earnings · Regulatory · M&A | 122 patents Pharmaceutical formulation stability and drug synthesis for small‑molecule and biologic therapeutics | 1 launch · 1 partnership · 1 award |
| 2 | Intas Provider of formulation development, drug manufacturing, and marketing activities 80Market top 15%Fin. health top 24%Funding top 28%Moat top 28% All 11 signals ▾Markettop 15% Fin. healthtop 24% Fundingtop 28% Moattop 28% Talenttop 28% Partnerstop 37% Producttop 37% Growthtop 49% Techbottom 45% Newsbottom 45% Globalbottom 45% Market: 21,220 employees (top 4% of Traditional Pharmaceuticals) · Revenue ~$2.5B Fin. health: Revenue ~$2.5B · Revenue +9% YoY rank vs industry peers · Fliar Intelligence Index 80/100 | $2.5B FY2023 | $200M | 72 mo ago | +9% | 21,220 21,220 → 19,909 (-6%) · sector median -6% | Rajendra Kumar Co-CEO | 4 signals ▼56% Contracts · M&A | — | 4 job openings |
| 3 | Mankind Pharma 🦄 Pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical… 78Market top 16%Fin. health top 18%Moat top 22%Talent top 23% All 13 signals ▾Markettop 16% Fin. healthtop 18% Moattop 22% Talenttop 23% Fundingtop 28% Producttop 29% Patentstop 32% Globaltop 35% Newstop 47% Innovationtop 49% Partnersbottom 49% Techbottom 45% Growthbottom 44% Market: 1,579 employees (top 24% of Traditional Pharmaceuticals) · Revenue ~$1.5B Fin. health: Revenue ~$1.5B (FY2021) · Net margin 20.5% rank vs industry peers · Fliar Intelligence Index 78/100 | $1.5B FY2025 | $367M | 98 mo ago | +21% | 1,579 | Greesh Juneja Co-Founder | 33 signals ▼61% Earnings · M&A · Regulatory | 133 patents Small-molecule GPR119 agonists and JAK1 inhibitors for metabolic and inflammatory therapies | 1 job opening · 1 partnership · 1 award |
| 4 | Emcure Developer, manufacturer, and markets a broad range of pharmaceutical products 78Moat top 13%Fin. health top 22%Market top 24%Talent top 33% All 10 signals ▾Moattop 13% Fin. healthtop 22% Markettop 24% Talenttop 33% Fundingtop 36% Producttop 39% Techtop 43% Newstop 44% Growthtop 49% Globalbottom 48% Moat: Top 1% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 6/10 Fin. health: Revenue ~$942M (FY2016) · Net margin 12.4% rank vs industry peers · Fliar Intelligence Index 78/100 | $942M FY2025 | $50M | 149 mo ago | +19% | 6,811 6,811 → 9,088 (+33%) · sector median -6% | Satish Mehta Founder & CEO | 24 signals ▼52% Earnings · M&A · FDA approval | — | 1 partnership |
| 5 | Laurus Labs Pharmaceutical and biotechnology company 69Moat top 17%Product top 24%Market top 27%Fin. health top 27% All 12 signals ▾Moattop 17% Producttop 24% Markettop 27% Fin. healthtop 27% Fundingtop 28% Patentstop 28% Innovationtop 33% Newstop 42% Growthtop 50% Talentbottom 49% Techbottom 42% Globalbottom 42% Moat: Top 1% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 5/10 Product: 7 distinct product lines · 1 published app (9.9k installs) rank vs industry peers · Fliar Intelligence Index 69/100 | $778M FY2026 | $230M | 139 mo ago | +22% | 6,035 6,035 → 3,867 (-36%) · sector median -6% | Satyanarayana Chava Founder & CEO | 32 signals ▼24% Earnings · Capital raise · Regulatory | 415 patents Innovative synthesis, polymorph control, and formulation of small‑molecule pharmaceuticals. | 3 awards |
| 6 | Natco Pharma Developer and manufacturer of API and finish dosage forms 80Moat top 17%Patents top 23%Market top 26%Fin. health top 28% All 12 signals ▾Moattop 17% Patentstop 23% Markettop 26% Fin. healthtop 28% Talenttop 28% Innovationtop 29% Fundingtop 34% Newstop 34% Producttop 35% Growthtop 44% Techtop 44% Globalbottom 38% Moat: Top 2% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 4/10 Patents: 640 patents matched (strict assignee match) · 103 filings since 2022 vs 174 in 2017-21 rank vs industry peers · Fliar Intelligence Index 80/100 | $566M FY2025 | $167M | 102 mo ago | +16% | 4,590 4,590 → 2,687 (-41%) · sector median -6% | Venkaiah Nannapaneni Founder & Managing Director | 52 signals Earnings · Leadership · M&A | 640 patents Novel synthetic processes and formulations for oncology and targeted kinase inhibitor drugs | 1 award |
| 7 | Strides Arcolab Manufacturer of IP-led niche finished dosage formulations and soft gelatin capsules 72Market top 20%Fin. health top 22%Moat top 27%Funding top 28% All 9 signals ▾Markettop 20% Fin. healthtop 22% Moattop 27% Fundingtop 28% Growthtop 49% Innovationbottom 43% Patentsbottom 43% Globalbottom 40% Newsbottom 36% Market: 2,157 employees (top 17% of Traditional Pharmaceuticals) · Revenue ~$547M Fin. health: Revenue ~$547M (FY2022) · Net margin 42.4% rank vs industry peers · Fliar Intelligence Index 72/100 | $547M FY2025 | $189M | 93 mo ago | +18% | 2,157 | — | — | 16 patents Formulation and delivery technologies for oral and topical pharmaceuticals, especially rifaximin. | — |
| 8 | ERIs Life Sciences Manufacturer of pharmaceutical formulations for chronic diseases 69Fin. health top 25%Moat top 25%Product top 28%Market top 30% All 10 signals ▾Fin. healthtop 25% Moattop 25% Producttop 28% Markettop 30% Newstop 35% Talenttop 38% Fundingtop 40% Growthtop 42% Techbottom 43% Globalbottom 37% Fin. health: Revenue ~$344M (FY2022) · Net margin 4.6% Moat: Top 3% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 3/10 rank vs industry peers · Fliar Intelligence Index 69/100 | $344M FY2025 | $43M | 177 mo ago | +43% | 1,058 | Amit Bakshi Co-Founder & Managing Director | 22 signals Earnings · M&A · Regulatory | — | — |
| 9 | Marksans Pharma Provider of pharmaceutical drug formulation manufacturing services 60Product top 14%Innovation top 20%Fin. health top 30%Moat top 30% All 11 signals ▾Producttop 14% Innovationtop 20% Fin. healthtop 30% Moattop 30% Fundingtop 33% Markettop 48% Newstop 50% Talentbottom 49% Growthbottom 48% Globalbottom 37% Techbottom 30% Product: 6 distinct product lines · Company stage: Public Innovation: 6 product lines rank vs industry peers · Fliar Intelligence Index 60/100 | $269M FY2024 | $46M | 40 mo ago | +17% | 98 | Mark Saldanha Founder | 6 signals ▼70% Earnings · Regulatory · M&A | — | — |
| 10 | Caplin Point laboratories Manufacturer of a pharmaceutical generics and biotech products 45Fin. health top 19%Moat top 20%Funding top 39%Market top 40% All 8 signals ▾Fin. healthtop 19% Moattop 20% Fundingtop 39% Markettop 40% Newsbottom 44% Globalbottom 37% Growthbottom 32% Techbottom 23% Fin. health: Revenue ~$241M (FY2026) · Net margin 46.0% Moat: Top 3% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 4/10 rank vs industry peers · Fliar Intelligence Index 45/100 | $241M FY2025 | $31M | 88 mo ago | — | 750 | — | 5 signals ▼77% Earnings · Regulatory | — | — |
| 11 | Morepen Laboratories Manufacturer of active pharmaceutical ingredients, home diagnostics, over-the-counter, and generic medicines 57Product top 29%Moat top 31%Innovation top 32%Fin. health top 34% All 13 signals ▾Producttop 29% Moattop 31% Innovationtop 32% Fin. healthtop 34% Markettop 35% Partnerstop 35% Fundingtop 39% Patentstop 39% Talentbottom 49% Newsbottom 45% Techbottom 44% Growthbottom 40% Globalbottom 32% Product: 0 product launch events in 12 mo, 5 the year before · 5 distinct product lines Moat: Top 3% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 1/10 rank vs industry peers · Fliar Intelligence Index 57/100 | $216M FY2025 | $159M | 60 mo ago | +7% | 1,097 | Sanjay Suri CEO | 4 signals ▼80% Contracts · Regulatory · Earnings | 16 patents Novel solid dosage forms and polymorph manufacturing processes for cardiovascular and metabolic drugs | — |
| 12 | La Renon Provider of pharmaceutical products 82Moat top 14%Innovation top 20%News top 21%Fin. health top 25% All 11 signals ▾Moattop 14% Innovationtop 20% Newstop 21% Fin. healthtop 25% Producttop 25% Fundingtop 30% Markettop 32% Growthtop 35% Techtop 39% Talentbottom 49% Globalbottom 39% Moat: Top 4% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 7/10 Innovation: 6 product lines rank vs industry peers · Fliar Intelligence Index 82/100 | $199M FY2025 | $116M | 25 mo ago | +16% | 2,732 | Pankaj Singh Chairman & CEO | 8 signals ▲167% M&A | — | — |
| 13 | Nectar Lifesciences Manufacturer of cephalosporin APIs and generic formulations 53Product top 14%News top 30%Market top 31%Moat top 34% All 12 signals ▾Producttop 14% Newstop 30% Markettop 31% Moattop 34% Fundingtop 38% Fin. healthtop 45% Techtop 49% Talentbottom 49% Growthbottom 46% Innovationbottom 44% Globalbottom 37% Patentsbottom 34% Product: 9 distinct product lines · Company stage: Public News: 9 BI events in 12 mo (of 26 tracked, 6 types) · +350% YoY rank vs industry peers · Fliar Intelligence Index 53/100 | $198M FY2025 | $47M | 195 mo ago | -1% | 1,712 | Amit Chadah CEO | 9 signals ▲350% Buyback · Earnings · Acquisition | 7 patents Efficient manufacturing processes for cephalosporin antibiotics and key intermediates | — |
| 14 | Encube Ethicals Company offering contract development and manufacturing services for topical semisolid formulations 62News top 24%Fin. health top 25%Moat top 27%Tech top 30% All 11 signals ▾Newstop 24% Fin. healthtop 25% Moattop 27% Techtop 30% Markettop 33% Growthtop 35% Talenttop 38% Fundingtop 39% Globalbottom 42% Patentsbottom 34% Innovationbottom 19% News: 6 BI events in 12 mo (of 18 tracked, 5 types) · 6 high-value events (IPO/M&A/funding/contracts) in 12 mo Fin. health: Revenue ~$162M (FY2016) · Net margin 22.1% rank vs industry peers · Fliar Intelligence Index 62/100 | $162M FY2025 | $66M | 59 mo ago | +25% | 1,382 1,382 → 1,100 (-20%) · sector median -6% | Mehul Shah Founder & Managing Director | 6 signals M&A · IPO | 2 patents Topical drug delivery formulations for anti-inflammatory and antifungal skin therapies | — |
| 15 | BDR Pharmaceuticals Developer and manufacturer of APIs as well as finished products 62Innovation top 19%Moat top 21%Product top 22%Patents top 29% All 11 signals ▾Innovationtop 19% Moattop 21% Producttop 22% Patentstop 29% Markettop 33% Fin. healthtop 36% Fundingtop 38% Growthbottom 48% Globalbottom 37% Newsbottom 22% Techbottom 21% Innovation: 63 patents (top 27% of patent-holders) · 50 filings since 2022 vs 13 in 2017-21 Moat: Top 5% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 4/10 rank vs industry peers · Fliar Intelligence Index 62/100 | $135M FY2025 | $88M | 52 mo ago | +2% | 1,687 | — | — | 63 patents Oral solid dosage formulations for oncology and specialty drugs (e.g., olaparib, abiraterone). | — |
| 16 | Tirupati Medicare Manufacturer of pharmaceutical and nutraceutical products 48Talent top 28%Product top 30%Tech top 33%Moat top 36% All 12 signals ▾Talenttop 28% Producttop 30% Techtop 33% Moattop 36% Fin. healthtop 37% Fundingtop 39% Markettop 42% Patentsbottom 37% Globalbottom 37% Innovationbottom 34% Growthbottom 30% Newsbottom 21% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Product: 5 distinct product lines · Company stage: Series B rank vs industry peers · Fliar Intelligence Index 48/100 | $132M FY2025 | $52M | 82 mo ago | +6% | 611 611 → 1,139 (+86%) · sector median -6% | Dinesh Goyal Co-Founder & Managing Director | — | 2 patents Topical analgesic formulations using beta‑caryophyllene for pain and inflammation relief | 1 award |
| 17 | Orchid Pharma Company offering a suite of pharmaceutical solutions 64Moat top 21%Funding top 30%Product top 36%Market top 37% All 12 signals ▾Moattop 21% Fundingtop 30% Producttop 36% Markettop 37% Fin. healthtop 37% Talenttop 38% Techtop 43% Growthtop 44% Patentstop 44% Innovationbottom 49% Globalbottom 42% Newsbottom 37% Moat: Top 6% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 4/10 Funding: Raised $48.8M across 1 rounds · 1 rounds over 3 yrs (0.3/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $112M FY2025 | $49M | 35 mo ago | +12% | 1,648 1,648 → 1,892 (+15%) · sector median -6% | Kailasam Rao Founder & Managing Director | — | 27 patents Novel carbapenem antibiotics for treating resistant bacterial infections | — |
| 18 | Shilpa Medicare Manufacturer of APIs as well as finished formulations 57Product top 14%Patents top 24%Moat top 26%Innovation top 28% All 13 signals ▾Producttop 14% Patentstop 24% Moattop 26% Innovationtop 28% Fundingtop 28% Newstop 31% Partnerstop 31% Markettop 37% Fin. healthtop 44% Talentbottom 48% Techbottom 46% Globalbottom 42% Growthbottom 34% Product: 8 distinct product lines · Company stage: Public Patents: 356 patents matched (strict assignee match) · 76 filings since 2022 vs 145 in 2017-21 rank vs industry peers · Fliar Intelligence Index 57/100 | $101M FY2025 | $116M | 26 mo ago | -1% | 1,203 1,203 → 1,862 (+55%) · sector median -6% | Adam Levitt Co-CEO | 17 signals ▲89% Earnings · Contracts · Regulatory | 356 patents Advanced pharmaceutical formulations for injectable controlled-release and oral dispersible drug delivery | 3 job openings · 1 award |
| 19 | Virupaksha Manufacturer of active pharmaceutical ingredients and pharmaceutical intermediate compounds 64News top 26%Moat top 32%Tech top 34%Growth top 39% All 9 signals ▾Newstop 26% Moattop 32% Techtop 34% Growthtop 39% Fin. healthtop 42% Markettop 43% Fundingtop 47% Talentbottom 49% Globalbottom 32% News: 6 BI events in 12 mo (of 6 tracked, 2 types) · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo Moat: Top 6% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 1/10 rank vs industry peers · Fliar Intelligence Index 64/100 | $97M FY2025 | $13M | 23 mo ago | +6% | 1,018 | Chandra Gangavaram Founder & Managing Director | 6 signals IPO · Hiring | — | — |
| 20 | Malladi Manufacturer of chiral building blocks and specialty chemicals 53Moat top 28%Innovation top 36%Product top 36%Talent top 38% All 10 signals ▾Moattop 28% Innovationtop 36% Producttop 36% Talenttop 38% Markettop 45% Fundingtop 46% Fin. healthtop 46% Techbottom 49% Growthbottom 41% Globalbottom 37% Moat: Top 8% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 3/10 Innovation: 12 product lines rank vs industry peers · Fliar Intelligence Index 53/100 | $74M FY2025 | $36M | 50 mo ago | -7% | 659 659 → 769 (+17%) · sector median -6% | V Gopalakrishnan Co-Founder | — | — | — |
| 21 | Inventia Healthcare Manufacturer & developer of various oral solid oral drug delivery systems 55Patents top 19%Moat top 22%Innovation top 29%Talent top 38% All 12 signals ▾Patentstop 19% Moattop 22% Innovationtop 29% Talenttop 38% Producttop 42% Fundingtop 44% Markettop 45% Fin. healthtop 46% Techtop 48% Globalbottom 42% Growthbottom 36% Newsbottom 18% Patents: 82 patents matched (strict assignee match) · 40 filings since 2022 vs 19 in 2017-21 Moat: Top 8% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 5/10 rank vs industry peers · Fliar Intelligence Index 55/100 | $73M FY2025 | $42M | 70 mo ago | -19% | 972 972 → 1,082 (+11%) · sector median -6% | Pavan Bhat Co-CEO | — | 82 patents Pharmaceutical formulation technologies for stable, controlled-release drugs and impurity reduction | 1 launch · 1 expansion |
| 22 | Symbio Generrics CDMO manufacturer of APIs and Intermediates 22Talent top 28%Moat top 30%Funding top 43%Growth top 50% All 10 signals ▾Talenttop 28% Moattop 30% Fundingtop 43% Growthtop 50% Fin. healthtop 50% Marketbottom 43% Patentsbottom 36% Globalbottom 33% Techbottom 18% Innovationbottom 4% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Moat: Top 10% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 4/10 rank vs industry peers · Fliar Intelligence Index 22/100 | $51M FY2025 | $13M | 50 mo ago | -11% | 241 241 → 214 (-11%) · sector median -6% | Salim Shaikh Co-Founder | — | 2 patents Enzymatic, high‑yield, enantioselective production of ursodeoxycholic acid (bile‑acid synthesis). | 4 job openings |
| 23 | BioPlus Developer of novel therapeutics and manufacturer of pharmaceutical products 60Product top 30%Innovation top 34%Growth top 35%Moat top 36% All 11 signals ▾Producttop 30% Innovationtop 34% Growthtop 35% Moattop 36% Talenttop 38% Techtop 43% Fin. healthtop 48% Marketbottom 49% Fundingbottom 48% Globalbottom 37% Newsbottom 22% Product: 4 distinct product lines · Company stage: Series B Innovation: 4 product lines rank vs industry peers · Fliar Intelligence Index 60/100 | $34M FY2025 | $29M | 216 mo ago | +46% | 291 291 → 530 (+82%) · sector median -6% | Sundeep Aurora Chief Executive Officer | — | — | 7 job openings |
| 24 | Linux Laboratories Manufacturer of phamaceutical finished dosage formulations 42Moat top 36%Fin. health top 42%Market top 45%Talent bottom 49% All 8 signals ▾Moattop 36% Fin. healthtop 42% Markettop 45% Talentbottom 49% Fundingbottom 46% Techbottom 44% Growthbottom 36% Globalbottom 32% Moat: Top 13% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 1/10 Fin. health: Revenue ~$33.7M (FY2022) · Net margin 9.9% rank vs industry peers · Fliar Intelligence Index 42/100 | $34M FY2025 | $7M | 35 mo ago | +14% | 1,052 1,052 → 593 (-44%) · sector median -6% | Keerthivasan K Founder & Director | — | — | — |
| 25 | Amanta Healthcare Manufacturer of sterile liquid parenterals using Aseptic BFS & ISBM technology 53Product top 14%Innovation top 20%News top 24%Moat top 31% All 12 signals ▾Producttop 14% Innovationtop 20% Newstop 24% Moattop 31% Fundingtop 39% Growthtop 49% Talentbottom 49% Fin. healthbottom 48% Marketbottom 47% Techbottom 38% Partnersbottom 35% Globalbottom 32% Product: 12 distinct product lines · Company stage: Public Innovation: 12 product lines rank vs industry peers · Fliar Intelligence Index 53/100 | $33M FY2025 | $14M | 23 mo ago | -2% | 510 510 → 346 (-32%) · sector median -6% | Paras Mehta CFO | 24 signals ▲380% IPO · Announcements · Contracts | — | — |
| 26 | Apothecon Pharmaceuticals Manufacturer of active pharmaceutical ingredients, peptides, and complex drug formulations 69Funding top 20%Product top 22%Innovation top 25%Moat top 32% All 9 signals ▾Fundingtop 20% Producttop 22% Innovationtop 25% Moattop 32% Techtop 37% Fin. healthtop 37% Markettop 46% Growthbottom 49% Globalbottom 37% Funding: Raised $270M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Product: 8 distinct product lines · Company stage: PE rank vs industry peers · Fliar Intelligence Index 69/100 | $31M FY2025 | $270M | 2 mo ago | +45% | 652 | — | — | — | — |
| 27 | Integrace Health Provider of musculoskeletal disorders, pain management, and women's health therapy services 45Moat top 27%Funding top 39%Tech top 39%Market top 46% All 9 signals ▾Moattop 27% Fundingtop 39% Techtop 39% Markettop 46% Talentbottom 49% Newsbottom 48% Growthbottom 44% Fin. healthbottom 41% Globalbottom 37% Moat: Top 15% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 4/10 Funding: Raised $72.8M across 1 rounds · 1 rounds over 5 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $29M FY2025 | $73M | 56 mo ago | -6% | 822 822 → 586 (-29%) · sector median -6% | Ankit Singhal CFO | — | — | — |
| 28 | Emil Pharmaceutical Industries Manufacturer of generic drugs 40Moat top 37%Talent top 45%Fin. health top 46%Funding top 47% All 8 signals ▾Moattop 37% Talenttop 45% Fin. healthtop 46% Fundingtop 47% Markettop 50% Techbottom 47% Growthbottom 42% Globalbottom 32% Moat: Top 15% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 1/10 Talent: 2 named leaders on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 40/100 | $28M FY2025 | $15M | 38 mo ago | +10% | — | Shrirang Gadnis CEO | — | — | — |
| 29 | Eris Oaknet Healthcare Manufacturer of pharmaceutical products 50Innovation top 20%Product top 26%Moat top 38%Funding top 42% All 11 signals ▾Innovationtop 20% Producttop 26% Moattop 38% Fundingtop 42% Talenttop 45% Techbottom 48% Fin. healthbottom 45% Newsbottom 42% Marketbottom 38% Growthbottom 38% Globalbottom 29% Innovation: 6 product lines Product: 6 distinct product lines · Company stage: Acquired rank vs industry peers · Fliar Intelligence Index 50/100 | $25M FY2021 | $100M | 161 mo ago | -3% | 5 | Amit Bakshi Co-Founder & Managing Director | — | — | — |
| 30 | Eurolife Healthcare Manufacturer and distributor of healthcare formulations 37Innovation top 20%Moat top 28%Talent top 28%Product top 36% All 11 signals ▾Innovationtop 20% Moattop 28% Talenttop 28% Producttop 36% Fundingtop 47% Techbottom 47% Marketbottom 40% Globalbottom 37% Fin. healthbottom 29% Newsbottom 27% Growthbottom 25% Innovation: 11 product lines Moat: Top 16% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 4/10 rank vs industry peers · Fliar Intelligence Index 37/100 | $24M FY2020 | $20M | 78 mo ago | -20% | 55 | Mahendrakumar Omprakash Co-Founder | — | — | — |
| 31 | Unimark remedies Traditional vertically integrated pharmaceutical company 22Moat top 23%Product top 25%Talent top 35%Funding top 42% All 12 signals ▾Moattop 23% Producttop 25% Talenttop 35% Fundingtop 42% Innovationbottom 48% Patentsbottom 40% Globalbottom 39% Marketbottom 33% Growthbottom 30% Techbottom 30% Fin. healthbottom 28% Newsbottom 22% Moat: Top 17% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 8/10 Product: 7 distinct product lines · Company stage: Series C rank vs industry peers · Fliar Intelligence Index 22/100 | $23M FY2018 | $73M | 120 mo ago | -19% | 3 | Sonali Parekh Founder | — | 10 patents Efficient synthesis and formulation of chiral antibiotics and cardiovascular drugs | — |
| 32 | SAI Parenterals Provider of parenteral products and pharmaceutical services 45News top 28%Growth top 33%Moat top 39%Funding top 45% All 9 signals ▾Newstop 28% Growthtop 33% Moattop 39% Fundingtop 45% Fin. healthtop 45% Talentbottom 49% Marketbottom 43% Techbottom 41% Globalbottom 30% News: 15 BI events in 12 mo (of 15 tracked, 3 types) · 13 high-value events (IPO/M&A/funding/contracts) in 12 mo Growth: Revenue +6% YoY · Web rank 50,000,000 → 10,000,000 YoY rank vs industry peers · Fliar Intelligence Index 45/100 | $19M FY2025 | $6M | 11 mo ago | +6% | — | Vijitha Gorrepati Managing Director | 15 signals IPO · Capital raise · Funding | — | — |
| 33 | Azista Manufacturer of food, healthcare, aerospace products, and composite engineering applications 60Innovation top 20%Growth top 38%Talent top 38%Product top 40% All 10 signals ▾Innovationtop 20% Growthtop 38% Talenttop 38% Producttop 40% Moattop 42% Techtop 49% Fin. healthbottom 49% Fundingbottom 41% Marketbottom 39% Globalbottom 30% Innovation: 10 product lines Growth: Headcount 226 → 296 (+31%) across vintages · Revenue +23% YoY rank vs industry peers · Fliar Intelligence Index 60/100 | $19M FY2025 | $551K | 4 mo ago | +23% | 296 296 → 223 (-25%) · sector median -6% | Sandeep Palreddy Chief Executive Officer | — | — | 5 job openings |
| 34 | Celon Laboratories Manufacturer of oncology-based products 42Innovation top 20%Product top 26%Talent top 38%Funding top 40% All 11 signals ▾Innovationtop 20% Producttop 26% Talenttop 38% Fundingtop 40% Moattop 40% Techbottom 45% Marketbottom 44% Globalbottom 37% Growthbottom 31% Fin. healthbottom 30% Newsbottom 27% Innovation: 6 product lines Product: 6 distinct product lines · Company stage: Acquired rank vs industry peers · Fliar Intelligence Index 42/100 | $18M FY2025 | $61M | 120 mo ago | -7% | 525 525 → 582 (+11%) · sector median -6% | Ravindra V Co-Founder | — | — | 1 launch |
| 35 | Murli Krishna Pharma Manufacturer of formulation intermediate drugs 29Moat top 40%Talent top 45%Tech top 49%Funding top 50% All 8 signals ▾Moattop 40% Talenttop 45% Techtop 49% Fundingtop 50% Growthbottom 39% Marketbottom 36% Globalbottom 36% Fin. healthbottom 34% Moat: Top 20% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 1/10 Talent: 2 named leaders on record rank vs industry peers · Fliar Intelligence Index 29/100 | $17M FY2025 | $11M | 72 mo ago | -21% | 245 245 → 192 (-22%) · sector median -6% | Vijay K. Shastri Co-Founder & Director | — | — | — |
| 36 | 9M India Manufacturer of pharmaceutical formulations 57Growth top 11%Fin. health top 34%Talent bottom 45%Market bottom 40% All 7 signals ▾Growthtop 11% Fin. healthtop 34% Talentbottom 45% Marketbottom 40% Fundingbottom 39% Globalbottom 33% Techbottom 31% Growth: Revenue +166% YoY · Fresh capital in last 24 mo Fin. health: Revenue ~$17.3M (FY2025) · Net margin 28.3% rank vs industry peers · Fliar Intelligence Index 57/100 | $17M FY2025 | $595K | 20 mo ago | +166% | — | Ajay Agrawal Managing Director | — | — | 1 award |
| 37 | Sunways Manufacturer of ophthalmic and ENT products, along with medical devices 45Innovation top 30%Moat top 30%Product top 35%Funding top 44% All 11 signals ▾Innovationtop 30% Moattop 30% Producttop 35% Fundingtop 44% Talenttop 45% Fin. healthtop 48% Growthbottom 48% Marketbottom 45% Globalbottom 37% Newsbottom 32% Techbottom 28% Innovation: 3 product lines Moat: Top 20% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 4/10 rank vs industry peers · Fliar Intelligence Index 45/100 | $17M FY2024 | $15M | 43 mo ago | +10% | 520 | Pankaj Shroff Managing Director | — | — | — |
| 38 | Fleming Laboratories Developer, manufacturer, and exporter of niche & off-beat APIs 48Innovation top 20%Product top 22%Moat top 41%Funding top 43% All 10 signals ▾Innovationtop 20% Producttop 22% Moattop 41% Fundingtop 43% Talentbottom 49% Fin. healthbottom 47% Growthbottom 43% Globalbottom 43% Techbottom 41% Marketbottom 32% Innovation: 11 product lines Product: 11 distinct product lines · Company stage: PE rank vs industry peers · Fliar Intelligence Index 48/100 | $16M FY2025 | $14M | 29 mo ago | +14% | 274 | Jeyamuruga M CEO & Managing Director | — | — | — |
| 39 | Koye Manufacturer of essential drugs for primary specialty care 24Moat top 26%Talent top 28%Funding top 41%Market top 49% All 9 signals ▾Moattop 26% Talenttop 28% Fundingtop 41% Markettop 49% Newsbottom 42% Techbottom 33% Globalbottom 32% Growthbottom 28% Fin. healthbottom 26% Moat: Top 23% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 7/10 Talent: Analyst team rating 5/5 · 2 named leaders on record rank vs industry peers · Fliar Intelligence Index 24/100 | $15M FY2025 | $47M | 69 mo ago | -4% | 1,149 | Ravindra Yogesh Shenoy Co-Founder | — | — | — |
| 40 | VS International Manufacturer of pharmaceutical products, healthcare products, and medical devices 53Innovation top 36%Product top 36%Moat top 37%Growth top 38% All 10 signals ▾Innovationtop 36% Producttop 36% Moattop 37% Growthtop 38% Fin. healthtop 44% Talenttop 45% Fundingtop 49% Techbottom 42% Marketbottom 36% Globalbottom 29% Innovation: 6 product lines Product: 6 distinct product lines · Company stage: Series A rank vs industry peers · Fliar Intelligence Index 53/100 | $15M FY2025 | $9M | 43 mo ago | +33% | 63 | Vidyut Shah Co-Founder & MD | — | — | — |
| 41 | Vivimed Labs Manufacturer of APIs, formulations and specialty chemicals 13Funding top 38%Moat top 38%Tech bottom 43%Market bottom 40% All 8 signals ▾Fundingtop 38% Moattop 38% Techbottom 43% Marketbottom 40% Globalbottom 39% Newsbottom 36% Fin. healthbottom 23% Growthbottom 19% Funding: Raised $100M across 5 rounds · 5 rounds over 15 yrs (0.3/yr) Moat: Top 17% by revenue among 1485 tracked Biopharma Outsourcing companies · Editorial + unicorn rating 1/10 rank vs industry peers · Fliar Intelligence Index 13/100 | $14M FY2025 | $100M | 101 mo ago | -24% | 58 | — | — | — | 8 job openings |
| 42 | Sidmak Manufacturer of pharmaceutical products including tablets, capsules, and transdermal patches 21Talent bottom 45%Growth bottom 43%Market bottom 41%Fin. health bottom 39% All 7 signals ▾Talentbottom 45% Growthbottom 43% Marketbottom 41% Fin. healthbottom 39% Fundingbottom 37% Globalbottom 33% Techbottom 24% Talent: 1 named leader on record Growth: Revenue -6% YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 21/100 | $10M FY2025 | $3M | 19 mo ago | -6% | 175 | Vinayak Bhalani Owner & Director | — | — | — |
| 43 | Innovare Labs CMO that will be offering APIs and intermediates to branded and generic pharma companies globally 16Talent top 35%Moat top 42%Growth bottom 48%Funding bottom 41% All 8 signals ▾Talenttop 35% Moattop 42% Growthbottom 48% Fundingbottom 41% Marketbottom 36% Globalbottom 25% Fin. healthbottom 22% Techbottom 16% Talent: 4 named leaders on record Moat: Top 32% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 3/10 rank vs industry peers · Fliar Intelligence Index 16/100 | $9M FY2024 | $13M | 42 mo ago | -8% | 595 | Sunkary Gopal Co-Founder | — | — | — |
| 44 | Shield Manufacturer of drugs 16Moat top 47%Funding bottom 48%Tech bottom 47%News bottom 45% All 9 signals ▾Moattop 47% Fundingbottom 48% Techbottom 47% Newsbottom 45% Productbottom 39% Marketbottom 34% Growthbottom 33% Globalbottom 32% Fin. healthbottom 26% Moat: Top 32% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 1/10 Funding: Raised $10.4M across 5 rounds · 5 rounds over 12 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 16/100 | $9M FY2025 | $10M | 44 mo ago | -3% | 518 | — | 4 signals ▼56% Buyback · Funding | — | — |
| 45 | Arinna Lifesciences Developer and marketer of specialty pharmaceutical drugs for the central nervous system 13Moat top 38%Funding bottom 47%Growth bottom 42%News bottom 42% All 8 signals ▾Moattop 38% Fundingbottom 47% Growthbottom 42% Newsbottom 42% Fin. healthbottom 42% Globalbottom 37% Marketbottom 32% Techbottom 18% Moat: Top 33% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 5/10 Funding: Raised $11.2M across 5 rounds · 5 rounds over 11 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 13/100 | $9M FY2025 | $11M | 83 mo ago | +10% | 322 | — | — | — | — |
| 46 | NanoPhyto Pharmacy Developer of medicines for chronic venous insufficiency, urinary incontinence & pain care 29Tech top 26%Growth top 31%Talent bottom 45%Funding bottom 37% All 8 signals ▾Techtop 26% Growthtop 31% Talentbottom 45% Fundingbottom 37% Moatbottom 30% Globalbottom 29% Fin. healthbottom 27% Marketbottom 18% Tech: 41 technologies across 5/8 capability areas · Cloud: Amazon S3, Amazon Web Services Growth: Revenue +21% YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 29/100 | $891K FY2025 | $377K | 13 mo ago | +21% | — | Anondeep Ganguly Founder | — | — | — |
| 47 | Avesthagen Life science company operating at the intersection of food, pharma, and agri-technologies 27Innovation top 16%Patents top 31%Talent top 38%Moat top 42% All 11 signals ▾Innovationtop 16% Patentstop 31% Talenttop 38% Moattop 42% Fundingtop 47% Techtop 50% Globalbottom 42% Growthbottom 25% Marketbottom 24% Newsbottom 18% Fin. healthbottom 15% Innovation: 124 patents (top 16% of patent-holders) Patents: 124 patents matched (strict assignee match) · Latest publication 2018 rank vs industry peers · Fliar Intelligence Index 27/100 | $189K FY2024 | $48M | 121 mo ago | -52% | 105 | Villoo Morawala-Patell Founder & Managing Director | — | 124 patents Genetically engineered crops improving stress tolerance and nitrogen-use efficiency | 2 launchs |
| 48 | Indiabulls Pharmaceuticals Manufacturer of generic products and medical devices for both chronic and acute therapies 5Talent top 41%Moat bottom 42%Tech bottom 40%Funding bottom 37% All 8 signals ▾Talenttop 41% Moatbottom 42% Techbottom 40% Fundingbottom 37% Globalbottom 37% Marketbottom 20% Fin. healthbottom 10% Growthbottom 8% Talent: Analyst team rating 4/5 · 1 named leader on record Moat: Top 99% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 8/10 rank vs industry peers · Fliar Intelligence Index 5/100 | $2K FY2025 | $48M | 103 mo ago | — | 22 | Nikhil Chari Co-Founder & CEO | — | — | — |
| 49 | Twilight Litaka Pharma Twilight Litaka Pharma Ltd is an India based company engaged in the pharmaceutical business. 9Funding top 47%Moat bottom 48%Global bottom 39%News bottom 27% All 6 signals ▾Fundingtop 47% Moatbottom 48% Globalbottom 39% Newsbottom 27% Fin. healthbottom 26% Marketbottom 22% Funding: Raised $56.2M · 1 rounds over 14 yrs (0.1/yr) Moat: Top 39% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 0/10 rank vs industry peers · Fliar Intelligence Index 9/100 | — | $56M | 169 mo ago | — | 5 | — | — | — | — |
| 50 | Claris Lifescences Online platform for pharmaceutical manufacturing and injectable therapies 6Funding top 47%Talent bottom 49%Global bottom 37%News bottom 36% All 6 signals ▾Fundingtop 47% Talentbottom 49% Globalbottom 37% Newsbottom 36% Marketbottom 22% Growthbottom 10% Funding: Raised $20.0M across 4 rounds · 4 rounds over 20 yrs (0.2/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 6/100 | — | $20M | 149 mo ago | — | 47 | Arjun Handa CEO | — | — | — |
Top 12 Traditional Pharmaceuticals companies in India
#1
Late Stage · Vadodara, Gujarat · founded 2010 · 652 employees$270Mraised▾
Late Stage · Vadodara, Gujarat · founded 2010 · 652 employees
Manufacturer of active pharmaceutical ingredients, peptides, and complex drug formulations. They provide finished dosage forms, intermediates, and products under pipeline. The company specializes in contract manufacturing services, including technology transfer and commercial production. Capabilities include formulation development, global-grade manufacturing, and strategic partnerships to deliver compliance and scalability.
Fliar Intelligence Index™ 69how this company ranks against its industry peers
Funding
top 20%Product
top 22%Innovation
top 25%Moat
top 32%Tech
top 37%Fin. health
top 37%Funding: Raised $270M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round PE (Apr 2026)
Product: 8 distinct product lines · Company stage: PE
Innovation: 8 product lines
Funding rounds
- Apr 2026PE$270M
Investors
Everstone Capital
Tech stack
Amazon CloudfrontAmazon Web ServicesBootstrapChart.JsCloudflareContact Form 7
#2
Public · Hyderabad, Telangana · founded 2001$5.8Mraised▾
Public · Hyderabad, Telangana · founded 2001
Provider of parenteral products and pharmaceutical services. It offers sterile dry powder injections and sterile liquid injections, including prefilled syringes, ampoules, and vials. Its facilities includes a range of products, including oral tablets, capsules, liquids, ointments, gels, and exclusive cephalosporin formulations.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
News
top 28%Growth
top 33%Moat
top 39%Funding
top 45%Fin. health
top 45%Talent
bottom 49%News: 15 BI events in 12 mo (of 15 tracked, 3 types) · 13 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: IPO, Capital raise, Funding
Growth: Revenue +6% YoY · Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo
Moat: Top 19% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 1/10
Funding rounds
- Jul 2025Series A$5.8M
Founders & team
Investors
Samarsh Capital, Blue Lotus Capital, Vyom Partners, MYCap Investments
Tech stack
Apache Http ServerOpen GraphRadix UiReactReact RouterShadcn/Ui
#3
Funding Raised · Hyderabad, Telangana · founded 2014 · 296 employees$551.5Kraised▾
Funding Raised · Hyderabad, Telangana · founded 2014 · 296 employees
Manufacturer of food, healthcare, aerospace products, and composite engineering applications. It provides food and nutrition products, end-to-end design and development of space-associated infrastructure, and healthcare products. It develops high-temperature engineering applications. The company also provides design, manufacturing, testing, and supply chain management solutions.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Innovation
top 20%Growth
top 38%Talent
top 38%Product
top 40%Moat
top 42%Tech
top 49%Innovation: 10 product lines
Growth: Headcount 226 → 296 (+31%) across vintages · Revenue +23% YoY · Fresh capital in last 24 mo
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 19k LinkedIn followers
Hiring (LinkedIn): 5 hiring posts in 12 mo (public) · momentum +5 · hiring: Digital Marketing Executive, Business Development Manager
Funding rounds
- Feb 2026Grant (prize money)$551.5K
Founders & team
Investors
IN-SPACe, Forge
Tech stack
Apache Http ServerBootstrapBootstrap IconsCdnjsCloudflareCodeigniter
#4
Public · Raichur, Karnataka · founded 1987 · 1203 employees$116.4Mraised▾
Public · Raichur, Karnataka · founded 1987 · 1203 employees
Shilpa Medicare is focused on manufacturing API, fine chemicals, intermediates, herbal products, specialty chemical products, and formulations. The company has eight manufacturing facilities, out of which seven are located in India. The company's contract service offering includes manufacturing of APIs, formulations, development of new drug delivery systems (NDDS) and biopharmaceuticals. The company's manufacturing facilities are approved by US-FDA, EDQM, and KFDA.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Product
top 14%Patents
top 24%Moat
top 26%Innovation
top 28%Funding
top 28%News
top 31%Product: 8 distinct product lines · Company stage: Public
Patents: 356 patents matched (strict assignee match) · 76 filings since 2022 vs 145 in 2017-21 · Latest publication 2026
Moat: Top 6% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 1/10 · IP moat: 356 patents
Audience (LinkedIn): 60k LinkedIn followers
Hiring (LinkedIn): 3 hiring posts in 12 mo (public) · momentum +3 · hiring: Area Therapy Managers (ATM), Area Therapy Manager
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Apr 2024Post IPO$59.9M
- Dec 2016Post IPO$25.5M
- Apr 2014Post IPO$12.5M
- May 2012Post IPO$1.8M
Founders & team
Investors
ICICI Prudential Asset Management Company, Bandhan Mutual Fund, SBI Life Insurance, TA, Baring Private Equity Partners, Tano Capital
Tech stack
CdnjsCloudflareCloudflare Browser InsightsGoogle AnalyticsGoogle Font ApiGoogle Hosted Libraries
#5
Series C · Ahmedabad, Gujarat · founded 2007 · 2732 employees$115.6Mraised▾
Series C · Ahmedabad, Gujarat · founded 2007 · 2732 employees
Provider of pharmaceutical products. It specializes in medicines and formulations for chronic diseases such as nephrology, urology, neurology, cardiac, gastroenterology, critical care, respiratory, and gynecology. It offers a range of products for chronic illnesses and diseases.
Fliar Intelligence Index™ 82how this company ranks against its industry peers
Moat
top 14%Innovation
top 20%News
top 21%Fin. health
top 25%Product
top 25%Funding
top 30%Moat: Top 4% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 7/10
Innovation: 6 product lines
News: 8 BI events in 12 mo (of 19 tracked, 3 types) · +167% YoY · 8 high-value events (IPO/M&A/funding/contracts) in 12 mo
Funding rounds
- Apr 2024Series C$70M
- Jan 2021Series B$30M
- Jun 2015Series A$15.6M
Founders & team
Investors
A91 Partners, Peak XV Partners, ChrysCapital, Pankaj Singh Family Trust, Avendus, Creador
Tech stack
BootstrapCloudflareCloudflare Browser InsightsContact Form 7Core-JsElementor
#6
Public · Ahmedabad, Gujarat · founded 1997 · 510 employees$14.1Mraised▾
Public · Ahmedabad, Gujarat · founded 1997 · 510 employees
Manufacturer of sterile liquid parenterals using Aseptic BFS & ISBM technology. It offers formulations, fluid therapy, ophthalmics, respiratory solutions, and medical devices. The company provides contract services including formulation development, scaled-up manufacturing, and lab-scale trials. Regulatory services and product partnering are also key offerings. Manufacturing facilities adhere to stringent regulatory standards and have received international approvals. A focus on product partnering facilitates collaborations with pharmaceutical companies.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Product
top 14%Innovation
top 20%News
top 24%Moat
top 31%Funding
top 39%Growth
top 49%Product: 12 distinct product lines · Company stage: Public
Innovation: 12 product lines
News: 24 BI events in 12 mo (of 30 tracked, 7 types) · +380% YoY · 20 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 10k LinkedIn followers
Hiring (LinkedIn): 3 hiring posts in 12 mo (public) · hiring: Area Sales Executive, IPQA Incharge
Funding rounds
- Jul 2024Series B$2.4M
- May 2016Series B$1.2M
- Jan 2013Series B$8.3M
- Aug 2008Series A$4.6M
Founders & team
Investors
TCHF, Marck Remedies, IFCI Venture Capital Funds, M N J Jackson, Modern Marine, Agotherm Engineers
Tech stack
AosApache Http ServerBootstrapBootstrap IconsCdnjsCloudflare
#7
Public · Hyderabad, Telangana · founded 1984 · 21757 employees$3.8Mraised▾
Public · Hyderabad, Telangana · founded 1984 · 21757 employees
Multinational pharmaceutical company that develops and manufactures innovative and medicines to improve patient health. Its portfolio includes Active Pharmaceutical Ingredients, generics, branded generics, biosimilars, and over-the-counter pharmaceutical products. Company offers a wide range of pharmaceuticals across various therapeutic categories, including gastrointestinal, cardiovascular, pain management, oncology, anti-infectives, pediatrics, and dermatology.
Fliar Intelligence Index™ 83how this company ranks against its industry peers
Moat
top 12%Market
top 18%Tech
top 21%Product
top 23%Fin. health
top 26%Patents
top 27%Moat: Top 1% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 6/10 · IP moat: 122 patents
Market: 21,757 employees (top 1% of Traditional Pharmaceuticals) · Revenue ~$4.0B · ~7% of tracked Traditional Pharmaceuticals revenue (1067 cos, FY2025)
Tech: 59 technologies across 5/8 capability areas · Cloud: Amazon S3, Amazon Web Services · Observability: Microsoft Clarity, Sentry
Audience (LinkedIn): 1.9M LinkedIn followers — 38.7% of this cohort's audience
Activity (LinkedIn): 1 product launches · 1 partnerships · 1 awards (incl. Radia Hospital) announced in 12 mo
Funding rounds
- Feb 2025Post IPO$3.4M
- 2022Post IPO—
- Oct 2016Grant (prize money)$354.2K
Founders & team
Investors
Gates, Digit Insurance, ICICI Venture, Broad Venture Capital, Life Insurance Corporation of India, GENESIS Biomed
Tech stack
Amazon S3Amazon Web ServicesAzureBootstrapCloudflareCloudflare Bot Management
#8
Series B · Hyderabad, Telangana · founded 2003 · 1018 employees$12.8Mraised▾
Series B · Hyderabad, Telangana · founded 2003 · 1018 employees
Manufacturer of active pharmaceutical ingredients and pharmaceutical intermediate compounds. The company produces substances providing pharmacological activity used in medications. It also manufactures key components used in the production of life-saving medications. The company focuses on manufacturing from starting materials.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
News
top 26%Moat
top 32%Tech
top 34%Growth
top 39%Fin. health
top 42%Market
top 43%News: 6 BI events in 12 mo (of 6 tracked, 2 types) · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: IPO, Hiring
Moat: Top 6% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 1/10
Tech: 35 technologies across 4/8 capability areas · Devops: Nginx · Security: Http/3, Recaptcha
Funding rounds
- Jul 2024Series B$12.8M
Founders & team
Investors
Gavva Consultancy, Sigachi laboratories, Fkmanagements, S2 Engineering, Chandak Laboratories, Sanjay Technical Services
Tech stack
Apache Http ServerContact Form 7Core-JsElementorExpressGodaddy
#9
Early Stage · Valsad, Gujarat · founded 1983 · 175 employees$2.9Mraised▾
Early Stage · Valsad, Gujarat · founded 1983 · 175 employees
Manufacturer of pharmaceutical products including tablets, capsules, and transdermal patches. The company develops and manufactures pharmaceutical products utilizing technology platforms. It focuses on developing and manufacturing essential drugs. The firm offers manufacturing for pellets, tablets, hard gelatin capsules, and transdermal patches. Quality control and assurance departments support the quality management system.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Talent
bottom 45%Growth
bottom 43%Market
bottom 41%Fin. health
bottom 39%Funding
bottom 37%Global
bottom 33%Talent: 1 named leader on record
Growth: Revenue -6% YoY · Fresh capital in last 24 mo
Market: 175 employees · Revenue ~$10.1M · Top 30% by revenue among 1067 tracked Traditional Pharmaceuticals peers
Funding rounds
- Oct 2024Unattributed$1.9M
- Apr 2010Unattributed$989.9K
Founders & team
Investors
nirmitexports, Mackinonenterprise, Shanghavi Finance, Sun Pharma
Tech stack
PhpGoogle MapsBootstrapNginxLightboxJquery
#10
Public · Chennai, Tamil Nadu · founded 1992 · 1648 employees$48.8Mraised▾
Public · Chennai, Tamil Nadu · founded 1992 · 1648 employees
Orchid Chemicals & Pharmaceutical is involved in the development and manufacturing of diverse bulk actives, formulations, and nutraceuticals. Their pharmaceutical solutions include APIs, finished dosage forms, NCE discovery, novel drug delivery systems and CRAMS services. Orchid’s manufacturing infrastructure includes USFDA and UK MHRA approved API and dosage form facilities are located at Chennai and Aurangabad.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Moat
top 21%Funding
top 30%Product
top 36%Market
top 37%Fin. health
top 37%Talent
top 38%Moat: Top 6% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 4/10 · IP moat: 27 patents
Funding: Raised $48.8M across 1 rounds · 1 rounds over 3 yrs (0.3/yr) · Last round Post IPO (Jun 2023)
Product: 0 product launch events in 12 mo · 2 distinct product lines · Company stage: Public
Audience (LinkedIn): 45k LinkedIn followers
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Jun 2023Post IPO$48.8M
Founders & team
Investors
MIT, Societe Generale, Quant, Carnelian, 238 Plan Associates, Hospira
Tech stack
Animate.CssAosApache Http ServerBootstrapEmotionGoogle Analytics
#11
Seed · Kolkata, West Bengal · founded 2010$377.1Kraised▾
Seed · Kolkata, West Bengal · founded 2010
Developer of medicines for chronic venous insufficiency, urinary incontinence & pain care. The company produces phyto formulations such as capsules and oils for the treatment of the venous system, including varicose veins and CVI. Also, it offers products for treating and healing feet.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Tech
top 26%Growth
top 31%Talent
bottom 45%Funding
bottom 37%Moat
bottom 30%Global
bottom 29%Tech: 41 technologies across 5/8 capability areas · Cloud: Amazon S3, Amazon Web Services · Observability: Microsoft Clarity, Sentry
Growth: Revenue +21% YoY · Fresh capital in last 24 mo
Talent: 1 named leader on record
Funding rounds
- May 2025Angel$70.1K
- Nov 2024Seed$233.5K
- Apr 2024Seed$558.2K
Founders & team
Investors
Sunicon, Bakhtawar House
Tech stack
ShopifyBootstrapHandlebarsBooster Page Speed OptimizerBitespeedUnpkg
#12
Public · Delhi, Delhi · founded 1991 · 1579 employees$367.2Mraised▾
Public · Delhi, Delhi · founded 1991 · 1579 employees
Pharmaceutical company engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations. It focuses on a diverse range of therapeutic areas, catering to both acute and chronic conditions, include Anti-infectives, Cardiovascular, Gastrointestinal, Respiratory, Vitamins, Minerals, and Nutrients, Anti-diabetic, Neuro/Central Nervous System, and Gynaecology. Its most notable brands include Nurokind, Telmikind, Moxikind, Amlokind, and Gudcef.
Fliar Intelligence Index™ 78how this company ranks against its industry peers
Market
top 16%Fin. health
top 18%Moat
top 22%Talent
top 23%Funding
top 28%Product
top 29%Market: 1,579 employees (top 24% of Traditional Pharmaceuticals) · Revenue ~$1.5B · ~3% of tracked Traditional Pharmaceuticals revenue (1067 cos, FY2025)
Fin. health: Revenue ~$1.5B (FY2021) · Net margin 20.5% · Revenue +21% YoY
Moat: Top 1% by revenue among 1067 tracked Traditional Pharmaceuticals companies · Editorial + unicorn rating 1/10 · IP moat: 133 patents
Audience (LinkedIn): 1M LinkedIn followers — 20.0% of this cohort's audience
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Officier / Sr. Officer / Executive / Sr. Executive
Activity (LinkedIn): 1 partnerships · 1 awards (incl. Denovo Sciences) announced in 12 mo
Funding rounds
- Apr 2018PE$350M
- Apr 2007Series A$17.2M
Founders & team
Investors
Monet, ChrysCapital, Arora Family, HarbourVest Partners, Capital Group, Cairnhill
Tech stack
BootstrapCdnjsCloudflareFingerprintjsFont AwesomeGoogle Analytics
Funding & investor landscape
$3.4Btotal disclosed funding
83companies funded
187disclosed rounds
1rounds last 90 days
Most active investors
Notable founders
Vijitha Gorrepati
Managing Director · SAI Parenterals
Sandeep Palreddy
Chief Executive Officer · Azista
Srinivas Male
Managing Director · Azista
Adam Levitt
Co-CEO · Shilpa Medicare
Santosh Mahil
Co-CEO · Shilpa Medicare
Pankaj Singh
Chairman & CEO · La Renon
Paras Mehta
CFO · Amanta Healthcare
Erez Israeli
CEO · Dr. Reddy's Laboratories
Milan Kalawadia
Chief Executive Officer · Dr. Reddy's Laboratories
Chandra Gangavaram
Founder & Managing Director · Virupaksha
Vinayak Bhalani
Owner & Director · Sidmak
Kailasam Rao
Founder & Managing Director · Orchid Pharma
Prism market signals · India · country-scoped Prism corpus, 431,747 docs
Market landscape — 10 sub-themes by coverage
Share of Traditional Pharmaceuticals coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · India
How research on Drug Discovery is moving in India
A read on the academic research around Drug Discovery — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 5,175 India-affiliated papers.
research sentiment over time
201020202026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 68% → 75% across 2010–2026.
top research entities
- Amicable Knowledge Solution University177
- Saveetha University139
- National Institute of Pharmaceutical Education and Research129
- Rajiv Gandhi University of Health Sciences111
- Academy of Scientific and Innovative Research106
leading researchers
Shopnil Akash · Mishra, Deepak · Samdariya, Keerti · Rai, Piyush Kant · Mishra, Shaily · Kumar, Sanjeet · Taj Mohammad · Anas Shamsi
▲
Breakthroughs1,084 · 21%
▲ 12%→21% share
▲1.8× share momentum0 median citations98% since 2021mostly methods-led
Computational biology breakthroughs are surging — Indian drug discovery papers rose from 3 to 154, with virtual screening newly contributing 117.
rising sub-themes (early→recent)
- Computational biology3→154
- Docking (animal)1→124
- In silico2→108
- Identification (biology)1→57
- Chemical space1→45
Newly emergingVirtual screening 0→117 · Precision medicine 0→91 · Personalized medicine 0→75
Landmark Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals · 747 cites
◆
Advancements2,803 · 54%
▲ 46%→54% share
▲1.2× share momentum0 median citations98% since 2021mostly reviews
In silico and docking advancements are intensifying — papers grew from 4→503 and 2→630 respectively across Indian institutions.
rising sub-themes (early→recent)
- Docking (animal)2→630
- In silico4→503
- Virtual screening3→491
- Computational biology9→433
- Pharmacology7→274
Newly emergingRepurposing 0→139 · ADME 0→129 · Drug delivery 0→121
Landmark Perovskites in catalysis and electrocatalysis · 1,740 cites
▼
Concerns614 · 12%
▼ 19%→12% share
▼0.6× share momentum0 median citations96% since 2021mostly reviews
Concern-flagged research is shrinking in field-share (19%→12%), though natural-product and drug-development papers still climbed to 75 and 103.
rising sub-themes (early→recent)
- Drug development2→103
- Natural product1→75
- Pharmacology3→63
- Computational biology6→64
- Identification (biology)1→42
Newly emergingNatural (archaeology) 0→68 · Disease 0→62 · Action (physics) 0→57
Landmark Insoluble drug delivery strategies: review of recent advances and business prospects · 1,326 cites
RESEARCH HOTSPOTS · India
Where drug discovery is researched across India
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Delhi-NCR367 · +0.51
Chennai170 · +0.49
Mumbai149 · +0.56
Hyderabad103 · +0.52
Pune102 · +0.53
Bengaluru96 · +0.62
Varanasi93 · +0.47
Kolkata84 · +0.49
Ahmedabad49 · +0.50
Guwahati29 · +0.44
PATENT SIGNAL · India
Who's filing drug discovery patents in India
India drug discovery patent filing is cooling — 24,008 filings from 8,000 assignees (2016–2025), led by CSIR, Lupin, Unilever; annual filings 2775→1886.
24,008 filings8,000 assigneespeak 2775/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- CSIR3065
- Lupin1775
- Unilever1713
- Reddys LAB DR1687
- Ranbaxy LAB1672
- Cipla1606
- Cadila Healthcare1589
- SUN Pharmaceutical IND1299
Common questions
How many Traditional Pharmaceuticals companies are there in India?
Radar tracks 1152 indexable Traditional Pharmaceuticals companies headquartered in India, India, that meet our profile-completeness bar.
What is the total funding raised by Traditional Pharmaceuticals companies in India?
The Traditional Pharmaceuticals companies in India on this list have raised a combined $3.4B in disclosed equity funding across 83 funded companies.
Which is the highest-funded Traditional Pharmaceuticals company in India?
Mankind Pharma is the highest-funded Traditional Pharmaceuticals company in India, with $367.2M in disclosed equity funding.
How many Traditional Pharmaceuticals companies in India are funded?
83 of the 1152 Traditional Pharmaceuticals companies in India on this list have disclosed at least one equity funding round.
How many Traditional Pharmaceuticals unicorns are there in India?
1 Traditional Pharmaceuticals company in India on this list is valued at $1B or more.
Who are the top investors in India Traditional Pharmaceuticals companies?
The most active investors in India Traditional Pharmaceuticals companies on this list include BIRAC, ChrysCapital, InvAscent, Baring Private Equity Partners, Brand Capital.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.